Infectious Disease Research Institute (IDRI)


Service Lines
Space Programming  •  Strategic Planning

The confluence of biomedical science and powerful philanthropy has made the Puget Sound Region a growing hub of global health research.  As a player in the broader global health landscape, IDRI needed to plan carefully how to house its dynamic workforce — while being a careful steward of its resources — thus growing its world presence intelligently.

IDRI expanded its base of for- and non-profit collaborators to include a newly formed TB Drug Discovery Partnership.  Funded by Eli Lilly & Company, IDRI acquired equipment and intellectual capital in the form of two former chemists from ICOS Corporation, recently purchased by Eli Lilly.  Roy Mann led an advisory team in conducting a program study to analyze IDRI’s current use of space and projected utilization trends for IDRI’s future housing needs.  IDRI’s success in part stems from its ongoing collaboration with large pharmaceutical companies, as well as ongoing programmatic interactions with key global health players in the region.  Thus, the analysis of future alternatives for IDRI took into consideration the broader collaborative context, and made recommendations that would position IDRI as an innovator.

IDRI is recognized as a key leader in the new partnership “Lilly not-for-profit Partnership for TB Early Phase Drug Discovery” which along with IDRI includes among others: Eli Lilly & Company, National Institute of Allergy and Infectious Diseases, Jubilant Biosys, Merck & Company, and the University of Washington Department of Global Health.  In addition to helping coordinate the Eli Lilly/ICOS transition, Mann and his team produced a program study that enables IDRI to frame discussions about its future growth with board members, key collaboration partners, and funding sources in an objective way.

Mann’s team played a critical role in helping IDRI understand its current and projected utilization of physical space.